Xinhua News Agency A U.S. biotechnology company launched a project on the use of embryonic stem cells to treat human blindness on the 22nd. In previous animal experiments, embryonic stem cell implantation effectively improved the visual abilities of experimental mice and restored visual function. This is the second embryonic stem cell experiment project approved by the U.S. Food and Drug Administration this year. This project was applied by the advanced cellular technology company headquartered in Massachusetts, and the first phase of the trial was for 12 blind people. The company’s chief scientific officer, Bob Lanza, said that previous animal experiments showed that the extraction of retinal cells from embryonic stem cells after implanted into experimental mice has achieved good results without causing tumors or other negative effects. "These (embryonic) cells do show special (effects) on animals, and if they get efficacy demonstration in human patients, it will be a home run," Lanza said. The first 12 patients to receive treatment were Stargard’s blind patients. Stargardt’s blindness is a recessive hereditary disease, also known as fundus macular dystrophy blindness, and there is no treatment at this stage.